Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 51 to 100 of 2500

TitleReference numberPublishedLast updated
Transcatheter aortic valve implantation (TAVI) for native aortic valve regurgitationIPG805
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancerTA1071
Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)TA1072
Topical antimicrobial dressings for locally infected leg ulcers: late-stage assessmentHTE27
Spesolimab for treating generalised pustular psoriasis flaresTA1070
Intrapartum careNG235
Targeted muscle reinnervation for managing limb amputation painIPG804
Caesarean birthNG192
Linzagolix for treating symptoms of endometriosisTA1067
Efgartigimod for treating antibody-positive generalised myasthenia gravisTA1069
Laparoscopic insertion of an inactive implant for gastro-oesophageal reflux diseaseIPG803
Somapacitan for treating growth hormone deficiency in people 3 to 17 yearsTA1066
Headaches in over 12s: diagnosis and managementCG150
Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (terminated appraisal)TA1068
Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiencyTA1065
Abortion careNG140
Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiencyTA1064
Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatmentTA1063
Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitorTA1062
Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancerTA1060
Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphomaTA1059
Digital therapy for chronic tic disorders and Tourette syndrome: early value assessmentHTE25
Omaveloxolone for treating Friedreich's ataxia in people 16 years and over (terminated appraisal)TA1061
Drug-eluting stents for treating coronary artery disease: late-stage assessmentHTE26
Artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin cancer pathway: early value assessmentHTE24
Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19TA878
COVID-19 rapid guideline: managing COVID-19NG191
Suspected cancer: recognition and referralNG12
Slide sheets for moving or repositioning a person: late-stage assessmentHTE23
Falls: assessment and prevention in older people and in people 50 and over at higher riskNG249
FallsQS86
Leniolisib for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and overHST33
Tislelizumab in combination for untreated advanced non-small-cell lung cancer (terminated appraisal)TA1058
Balloon disimpaction of the baby's head at emergency caesarean during the second stage of labourIPG800
Robot-assisted surgery for soft tissue procedures: early value assessmentHTE21
Robot-assisted surgery for orthopaedic procedures: early value assessmentHTE22
Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapyTA1055
Molnupiravir for treating COVID-19TA1056
Relugolix–estradiol–norethisterone for treating symptoms of endometriosisTA1057
Cladribine for treating active relapsing forms of multiple sclerosisTA1053
Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and overTA1054
Early and locally advanced breast cancer: diagnosis and managementNG101
Burosumab for treating X-linked hypophosphataemia in children and young peopleHST8
Olipudase alfa for treating acid sphingomyelinase deficiency (Niemann–Pick disease) type AB and type BHST32
Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and overTA1051
Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer (terminated appraisal)TA1052
Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitableTA1048
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemiaTA1049
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and overTA1050
Zolbetuximab with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinomaTA1046

Results per page

  1. 10
  2. 25
  3. 50
  4. All